Andy Batts
Long only, value, growth, momentum

Exact Sciences' Cologuard: A Game Changer For Colorectal Cancer Screening?

Executive summary:

  • Exact Sciences will present its case before an FDA panel of experts on March 27.
  • The company's Cologuard CRC test is expected to be cleared by the FDA this year.
  • The stock is significantly undervalued and could jump if approval is granted.


Exact Sciences (NASDAQ:EXAS), a molecular diagnostics company focused on the early detection and prevention of colorectal cancer, will present its case before an FDA panel of experts on March 27 to argue for approval of its new stool-based DNA screening test Cologuard for colorectal cancer ("CRC"). Currently Laboratory Corporation of America or LabCorp's (NYSE:LH) ColoSure is the only fecal DNA test for colorectal cancer available in the United States. If Cologuard...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details